OverviewSuggest Edit
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.
OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.
| Type | Public | |
| Founded | 2008 | |
| HQ | San Diego, US | Map |
| Website | otonomy.com |
Recent NewsAll News
- AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
- Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
Key People/Management at Otonomy
David A. Weber
Chief Executive Officer, President and Board Member
Elizabeth J. Ackermann
Vice President, Clinical Development
Carla da Luz Boren
General Counsel and Head of Human Resources
Julie D. Burgess
Vice President, Finance and Administration
Paul E. Cayer
Chief Financial & Business Officer
Barbara M. Finn
Vice President, Regulatory Affairs and Quality Assurance
Otonomy Office Locations
Otonomy has an office in San Diego
San Diego, US (HQ)
4796 Executive Dr
Otonomy Financials and Metrics
Otonomy Revenue
Otonomy's revenue was reported to be $745 k in FY, 2018 which is a 39.7% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2019) | 125.0k |
Gross profit (Q3, 2019) | (95.0k) |
Gross profit margin (Q3, 2019), % | (76%) |
Net income (Q3, 2019) | (10.0m) |
EBIT (Q3, 2019) | (10.1m) |
Market capitalization (15-Nov-2019) | 74.7m |
Closing stock price (15-Nov-2019) | 2.4 |
Cash (30-Sep-2019) | 16.3m |
EV | 73.4m |
Otonomy's current market capitalization is $74.7 m.
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k | 192.0k | 190.0k | 125.0k |
Cost of goods sold | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k | 213.0k | 203.0k | 220.0k |
Gross profit | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) | (21.0k) | (13.0k) | (95.0k) |
Gross profit Margin, % | (29%) | (22%) | (3%) | 10% | (96%) | (43%) | (11%) | (7%) | (76%) |
- Source: SEC Filings
Annual
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (27.1m) | (71.3m) | (11.4m) | (25.0m) | (37.5m) | (12.0m) | (23.7m) | (33.7m) | |
Depreciation and Amortization | 923.0k | 295.0k | 594.0k | 892.0k | 276.0k | 565.0k | 854.0k | ||
Inventories | 1.2m | 1.2m | 197.0k | 6.0k | |||||
Accounts Payable | 212.0k | 1.3m | 138.0k | 1.5m | (184.0k) | 321.0k | 123.0k | 837.0k | (90.0k) |
- Source: SEC Filings
| USD | Y, 2019 |
|---|---|
EV/EBIT | -7.3 x |
EV/CFO | -2.5 x |
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.8 x |
Otonomy Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 88 |
Patents Pending | 115 |
Phase III Trials Products | 2 |
Products | 1 |
Otonomy Online and Social Media Presence
233 Twitter followers
Otonomy has 233 Twitter Followers. The number of followers has decreased 0.8% quarter over quarter
Otonomy's Trends
Otonomy News and Updates
October 01, 2019
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns
August 01, 2019
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. EDT
May 06, 2019
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. EDT
May 02, 2019
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of …
May 01, 2019
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey …
April 11, 2019
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
Results expected in first half of 2020 Results expected in first half of 2020
Otonomy Blogs
November 05, 2019
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Content Import
Tue, 11/05/2019 - 16:14
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 5, 2019 at 4:13 PM EST
This release is a backf…
September 26, 2019
Otonomy to Present at the Cantor Global Healthcare Conference
Otonomy to Present at the Cantor Global Healthcare Conference
Michaela.Delmo…
Thu, 09/26/2019 - 16:06
Otonomy to Present at the Cantor Global Healthcare Conference
September 26, 2019 at 4:05 PM EDT
This release is a backfill from a News Wire
Gen…
August 13, 2019
Associate Scientist, Formulations
Position Objective: Execute formulation development work to support new products, develop drug products to support clinical development programs. Essential Functions: Understand and independently perform high-quality, hands-on experimental design of formulation development Review, compile and docume…
July 25, 2019
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
Content Import
Thu, 07/25/2019 - 16:05
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
Jul 25, 2019
This release is a backfill from a New…
July 03, 2019
David A. Weber, Ph.D.
Chief Executive Officer, President and Board Member David A. Weber, Ph.D. has served as our President and Chief Executive Officer and on our board of directors since late 2010. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a…
June 12, 2019
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
Content Import
Wed, 06/12/2019 - 08:01
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
Jun 12, 2019
This release is a backfill from a News Wire
…
Otonomy Frequently Asked Questions
When was Otonomy founded?
Otonomy was founded in 2008.
Who are Otonomy key executives?
Otonomy's key executives are David A. Weber, Elizabeth J. Ackermann and Carla da Luz Boren.
How many employees does Otonomy have?
Otonomy has 49 employees.
What is Otonomy revenue?
Latest Otonomy annual revenue is $745 k.
What is Otonomy revenue per employee?
Latest Otonomy revenue per employee is $15.2 k.
Who are Otonomy competitors?
Competitors of Otonomy include BeyondSpring, Inovio Pharmaceuticals and MyoKardia.
Where is Otonomy headquarters?
Otonomy headquarters is located at 4796 Executive Dr, San Diego.
Where are Otonomy offices?
Otonomy has an office in San Diego.
How many offices does Otonomy have?
Otonomy has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies